Objective: Menopause is often accompanied by vaginal discomfort including burning, itching, dryness, and spontaneous or provoked pain. Although the direct effects of estrogen withdrawal on vaginal cells are implicated, surgical menopause in rodents causes autonomic and sensory nerves to proliferate, suggesting that indirect effects mediated by changes in vaginal innervation may contribute. We assessed whether postmenopausal women display hormone-dependent changes in vaginal innervation.
T he consequences of menopause, with its declining production of reproductive hormones, are well known. In the human female reproductive tract, vaginal and uterine tissues are well imbued with estrogen receptors (ERs) and progesterone receptors, 1<4 and receptor activation results in wideranging effects such as endometrial cell proliferation, increased secretions, vascularization, and smooth muscle hypertrophy. 5 Reproductive hormones are therefore essential for the normal maintenance of the human reproductive tract.
Menopause is characterized by reductions in the normal circulating levels of reproductive hormones, leading to the loss of fecundity with accompanying changes in reproductive tract structure and function. Changes include atrophy of the vaginal epithelium and, in some cases, the vulva; decreased secretions; and changes in pH. 5<7 In some women, however, alterations are more profound and disconcerting. Many perimenopausal women experience itching, burning, dryness, and discomfort, and in some cases, pain that may be exacerbated with intercourse (dyspareunia). These symptoms are often severe enough to be considered for inclusion in the pelvic pain disorder, spontaneous generalized (dysesthetic) vulvodynia. 8 Both menopausal discomfort and symptoms of spontaneous vulvodynia are often relieved by systemic or topical hormone therapy (HT). 9, 10 The classic explanation as to why estradiol (E 2 ) is effective in reversing vaginal menopausal symptoms is that it acts directly on vaginal tissue ERs to restore normal target function. However, recent data suggest that the explanation may be more complex. Autonomic and sensory neurons express ERs 11<13 and are responsive to E 2 in culture, 14<16 supporting the idea that E 2 can act directly on peripheral neurons. In addition, E 2 induces uterine myometrium to produce neuromodulatory factors 17<19 and may do so in other parts of the reproductive tract. Indeed, in a rat model of menopause, we showed that overall vaginal innervation density increases by 50% 2 weeks after ovariectomy compared with intact cycling rats and that exogenous E 2 reduces innervation to preovariectomy levels. 20 In the present study, we assessed whether E 2 affects vaginal innervation density in postmenopausal women who received no HT, systemic HT, or topical HT.
METHODS

Participant and sample information
Postmenopausal women scheduled at the Kansas University Hospital to undergo surgery for treatment of stress urinary incontinence and/or pelvic organ prolapse by a single surgeon were invited to participate. Exclusion criteria included any history of genitourinary malignancy, pelvic radiation therapy, breast cancer, current severe atrophic vaginitis, or dysfunctional vaginal bleeding. No participants complained of vaginal pain or dyspareunia. Two women were also excluded because removing the tissue sample would have resulted in unacceptable tension at the vaginal incision closure site. All participants provided informed consent. The study was reviewed and approved by the University of Kansas Medical Center Human Subjects Committee and Institutional Review Board.
Full-thickness vaginal biopsy specimens (approximately 1 Â 2 cm) obtained from the anterior wall at the midvaginal level corresponding to the bladder neck from 20 postmenopausal women were included in this study. Specimens were obtained from the anterior vaginal wall in a sagittal orientation and included the edge of the midline vaginal incision. Biopsy specimens were removed using sharp dissection, and hemostasis was achieved using electrocautery before closure of the incision.
One group of nine women (50-73 y, 59.7 T 7.3 y) was not and had no history of receiving HT. A second group of six women (47-75 y, 61.2 T 4.0 y) was receiving systemic estrogen treatment before and at the time of surgery. Of these, four women were taking oral conjugated estrogens preparations (dose range, 0.3-1.25 mg/day), one used a transdermal estrogen patch (0.05 mg applied twice weekly), and one received regular intramuscular estrogen injections (exact dose not available). Five women (47-91 y, 63.6 T 7.3 y) applied topical vaginal estrogen cream. In these women, therapy was initiated at least 2 weeks before the date of surgery. The participants were administered 1 g of E 2 vaginal cream 0.01% (0.1 g active E 2 ) three times weekly at bedtime. The decision to begin topical estrogen therapy was made by each woman as part of the routine standard of care and not as part of the study protocol.
Tissue processing and immunostaining
Immediately after surgical excision, vaginal biopsy specimens were fixed in Zamboni's solution for 24 hours at 4-C and washed daily for 7 days using 0.01 M phosphate-buffered saline (PBS; pH 7.4). Tissue was transferred to 20% sucrose in PBS and cryoprotected at 4-C overnight, snap-frozen in isopentane precooled with liquid nitrogen, and stored at j80-C until cryosectioning at 10 Km. Stepped series of adjacent sections were thaw-mounted onto Fisherbrand Superfrost/Plus precleaned slides (Fisher Scientific, Pittsburgh, PA) and air-dried.
The sections were rinsed in PBS containing 0.3% Triton C-100 (PBST) and blocked for 60 minutes at room temper-ature in PBST containing 5% normal goat serum and 1% bovine serum albumin. Sections were incubated overnight in a humidified chamber at room temperature with antiserum against protein gene product (PGP) 9.5 (1:1200; rabbit polyclonal IgG; AbD Serotec), tyrosine hydroxylase (TH, 1:200; rabbit polyclonal IgG; Chemicon), and vasoactive intestinal peptide (VIP, 1:600; rabbit polyclonal IgG; Chemicon). The slides were then washed three times in PBST, followed by incubation with secondary antiserum for 1 hour at room temperature (goat antirabbit IgG conjugated to Cy3, 1:200, Jackson ImmunoResearch); the antibodies used in this study have been characterized previously. 21, 22 The slides were coverslipped using Fluoromount G.
Quantitative analyses
Digital microscopic images (Nikon Eclipse TE300 with an Optronics MagnaFire camera) were captured from three to four randomly selected sections from each vaginal specimen. In each section, four randomly selected fields from each of the superficial lamina propria (right below the dermoepidermal junction), deep lamina propria, and muscular layer were captured with Cy3 epifluorescence using a Â40 objective.
A stereology grid with line intersects at 10-Km intervals was superimposed randomly over the images. All grid intersects overlying nerve profiles were counted and divided by total points over vaginal tissue to yield the innervation density, as reported previously. 20, 21 
Statistical analysis
All values are presented as mean T SEM. Data were normally distributed, and statistical comparisons were made using one-way analysis of variance with post hoc testing using the Student-Newman-Keuls method for marker-positive axon densities across treatment groups. A relation between age and innervation density was explored using linear regression analysis. Differences were considered significant at P e 0.05.
RESULTS
Axons immunostained for the pan-neuronal marker PGP 9.5, were observed frequently throughout the vaginal lamina propria and muscularis ( Fig. 1A-C ), whereas few were found within the vaginal epithelium. PGP 9.5-immunoreactive (ir) axon density in postmenopausal women without HT was 0.94 T 0.07% (Figs. 1A and 2). In postmenopausal women receiving systemic HT, PGP 9.5-ir fiber density was 0.66 T 0.05% (Figs. 1B and 2), and in women with topical HT, it was 0.48 T 0.07% (Figs. 1C and 2). Densities in postmenopausal women with systemic HT and topical HT were both reduced compared with those in women without HT (P G 0.001). There was no association between innervation density and age in these groups.
TH-ir labels noradrenergic sympathetic fibers, and these were associated predominantly with smooth muscle cells comprising the vasculature and vaginal muscularis layer ( Fig. 1D-F) ; they were rarely seen in the superficial submucosa. TH-ir fiber densities were 0.38% T 0.05%, 0.30% T 0.04%, and 0.21% T 0.02% in postmenopausal women without HT, with systemic HT, and with topical HT, respectively (Fig. 2) . Differences were significant between women with topical HT and those without HT (P G 0.05) but not between women with systemic HT and those without HT.
Fibers immunoreactive for VIP, a neuropeptide expressed by cholinergic pelvic parasympathetic innervation, 23 were distributed beneath the epithelium and associated predominantly with vascular and nonvascular smooth muscle ( Fig. 1G-I) . VIP-ir nerve density was 0.33% T 0.04%, 0.24% T 0.02%, and 0.18% T 0.02% (Fig. 2) in postmenopausal women without HT, with systemic HT, and with topical HT, respectively. VIP density in women with topical HT was significantly lower than in women without HT.
Although TH-ir and VIP-ir fibers comprised most vaginal innervation, approximately a fifth of axons in all groups were negative for both markers (nonadrenergic, noncholinergic [NANC]). These NANC fibers are likely to represent predominantly unmyelinated sensory innervation. Indeed, immunostaining for calcitonin gene-related peptide (CGRP), a marker of presumptive sensory nociceptor axons, revealed small numbers of subepithelial fibers, which probably represent the bulk of the NANC population. The numbers of CGRP-ir fibers encountered seemed to be diminished in participants receiving oral or topical HT ( Fig. 1J-L ), but the low density of this population precluded reliable quantitative analysis.
To estimate the effect of HT on the NANC axon population, for each section, we summed contributions by TH-and VIP-ir axons, and subtracted this from PGP 9.5-ir total innervation (Fig. 2) . This derivative estimate showed that putative nociceptor innervation density also decreased in the presence of HT (P = 0.035).
DISCUSSION
Our observations revealed a rich plexus of innervation within the submucosal regions of the vaginal tissue, with relatively few intraepithelial axons. The plexus is composed predominantly of TH-and VIP-ir fibers in roughly equal proportions. This suggests that sympathetic and parasympathetic axons comprise the bulk of human vaginal innervation with smaller contributions by sensory fibers, consistent with earlier reports in humans 24<26 and rats. 20, 27, 28 Qualitative analysis showed that the NANC fiber population expresses CGRP, consistent with the presence of putative nociceptor axons.
Our quantitative findings show that innervation density changes as a function of HT status in postmenopausal women. This is concordant with an abundance of information regarding the effects of hormones on reproductive tract innervation. It has long been known that massive degenerative loss of uterine innervation occurs in rats and guinea pigs at term pregnancy 29<32 and that sympathetic axons are selectively pruned with rising estrogen levels in the proestrus/estrus phase of the estrous cycle in rats and mice. 22, 33, 34 This loss of innervation occurs through E 2 acting directly on the uterine smooth muscle target, leading to the production of prodegenerative and/or neurorepulsive proteins. 17, 18 These local prodegenerative conditions seem to dominate over the direct effects of E 2 , which tend to promote axon outgrowth and regeneration on sensory and sympathetic neurons. 15, 35, 36 We have shown recently that vaginal innervation in rats is also responsive to endogenous and exogenous E 2 , resulting in reductions in sympathetic and parasympathetic axons and in peptidergic sensory fibers. 20 Because rising E 2 levels at term pregnancy promote this denervation, we have proposed that these hormonal changes may underlie an important form of physiologically adaptive plasticity that may reduce pain sensitivity and facilitate delivery at parturition. 37 The findings presented here support the notion that human vaginal innervation is also responsive to E 2 . However, there are some limitations relative to studies in animal models. One caveat is that the protocol did not permit us to determine overall changes in vaginal volume associated with HT; therefore, we cannot exclude the possibility that some changes in nerve density occurred passively because of increased target size. However, it is generally believed that the primary hypertrophic effect of HT is restricted mainly to the vaginal epithelial cells, 38, 39 whereas our measurements were from the submucosal region, which is not thought to be substantively affected by HT. Furthermore, smooth muscle atrophy in the surgically meno-pausal rat is only partially reversed by E 2 . It therefore seems unlikely that the axonal remodeling seen here could be accounted for entirely by changes in target volume.
Reductions in vaginal autonomic nerves seen in women receiving HT are likely to have functional implications. Sympathetic axons from paravertebral ganglion neurons innervate blood vessels and nonvascular smooth muscle of the vaginal wall, and norepinephrine released by these axons elicits >adrenergic receptorYmediated contraction and vasoconstriction. 28, 40, 41 Conversely, parasympathetic neurons from the paracervical ganglion 42 project to vascular and nonvascular vaginal smooth muscle and release VIP, nitric oxide, and acetylcholine, all of which are reported to relax smooth muscle and promote vasodilation. 28, 40, 43 Accordingly, postmenopausal increases in these fibers could result in changes in vaginal smooth muscle tone and blood flow.
Vaginal smooth muscle tone is reportedly diminished in menopause. At least part of this is caused by the reduced smooth muscle content that occurs in the absence of reproductive hormones. 44 However, parasympathetic axons releasing nitric oxide can strongly inhibit vaginal smooth muscle contraction, 28 and their proliferation after menopause could also contribute to reduced tone. If so, HT could have beneficial effects by both increasing smooth muscle mass and by reducing the numbers of parasympathetic axons. It should be noted, however, that excitatory sympathetic innervation is also reduced by HT, giving rise to a more complex picture, and it will be of interest to assess physiologically which autonomic effects of HT may predominate.
Changes in hormone status also affect vaginal blood flow. The postmenopausal vagina is characterized by reduced vaginal blood flow, leading to decreased secretions and dryness of the vaginal mucosa. 10 This could be caused, in part, by an increase in sympathetic vasoconstrictor nerves. Therefore, reductions in sympathetic vasoconstrictor axons seen in women receiving HT could help increase vaginal blood flow. However, decreases in parasympathetic vasodilator fibers could partially offset increased vasodilatory tone; because the relative distributions of sympathetic and parasympathetic axons to the vaginal vasculature are not well described, the physiological consequences of altered vascular innervation density are yet to be defined. Nonetheless, it is known that E 2 strongly suppresses the release of pelvic parasympathetic nitric oxide, 45 which may suggest that improved blood flow with HT could be caused preferentially by reductions in vasoconstrictor nerves.
Although our sampling methods were not amenable to direct quantitation of sensory innervation, we did confirm the presence of putative nociceptor axons and showed that this NANC population was also responsive to E 2 . Both the quantitation of NANC axons and the assessment of CGRP-ir innervation confirmed that putative sensory nociceptor innervation was relatively abundant in postmenopausal women. This is of interest because CGRP is a potent vasodilator and postmenopausal vulvodynia is frequently associated with neurogenic genital inflammation, which could be caused by increased numbers of vasodilatory fibers. Accordingly, the reduction in NANC and CGRP-ir fibers induced by HT could explain that improvement seen after therapy is initiated. Furthermore, given that sympathetic innervation has been implicated in generalized vulvodynia, 46 the reduction in both putative nociceptor and sympathetic innervation may act synergistically to improve symptoms.
With the recognition that systemic HT can present specific health risks to some women, 44 there is increased emphasis in pursuing alternative approaches, and topical HT has gained additional favor. Topical estrogen therapy is often used to treat dysfunctional vaginal symptoms in postmenopausal women including burning, pain, and dyspareunia. 45 Even in women already taking systemic therapy, clinicians will frequently prescribe topical HT to maximize the concentrations of estrogen in vaginal and periurethral tissues. Our findings show that, at least with regard to HT modulation of vaginal innervation density, topical HT is in fact more effective in reducing the density of vaginal autonomic and sensory nerves. Therefore, not only is topical therapy associated with potentially lower health risk, but it represents a more efficacious treatment modality, consistent with its more profound effects on vaginal innervation.
CONCLUSIONS
We conclude that topical HT, and to a lesser extent systemic HT, represent effective means of reducing populations of sensory nociceptor and autonomic motor nerves in the postmenopausal vagina. Reductions in sensory innervation density are likely to play a role in the relief from burning, itching, and dyspareunia experienced by many postmenopausal women receiving HT. The effects on the autonomic nervous system seem more complex but are likely to impact the reductions in smooth muscle tone and vaginal dryness that occur in many instances after menopause.
